These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.
These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.
American Society of Hematology Annual Meeting 2023
Results 6
Oral Presentation | Dec 6, 2025
Long-Term Treatment Duration and Safety of Axatilimab Among Patients With Chronic Graft-Versus-Host Disease in AGAVE-201
View MaterialAbstract | Dec 9, 2023
Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
View MaterialAbstract | Dec 9, 2023
Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
View MaterialAbstract | Dec 9, 2023
Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant
View MaterialAbstract | Jun 11, 2023
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Efficacy and Safety Results from the AUGMENT-101 Phase 1/2 Study
View MaterialAbstract | Jun 11, 2023